Ionis develops and sells RNA-targeted medicines, including TRYNGOLZA, DAWNZERA and ZANVASTRO, and earns royalties on partner drugs such as SPINRAZA and Hibsago.
Ionis now sells its own medicines: DAWNZERA for hereditary angioedema, TRYNGOLZA, approved in severe hypertriglyceridemia in June 2026, and ZANVASTRO for Alexander disease, approved in September. Product sales were $31 million in the second quarter, and partners added royalties. Roche's sefaxersen cut proteinuria 43.1% in a Phase 3 in IgA nephropathy, with kidney-function data due at week 105. Two partnered heart trials failed in 2026. Ionis holds $2.1 billion and targets cash-flow breakeven in 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: TRYNGOLZA sales grow
Does TRYNGOLZA build meaningful sales in its larger new indication?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Ionis's own launches are growing; partner Roche reported Phase 3 sefaxersen data
Ionis now sells three of its own medicines, and partner GSK won approval for Hibsago
Ionis has three approved ASOs; bepirovirsen's PDUFA is the single event determining whether pipeline value matches breadth
Ionis has three approved drugs and two fresh Phase 3 wins, but the hepatitis B functional-cure PDUFA is the single event that rerates the stock
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Drug pages: Bepirovirsen
Disease areas: Kidney diseases, Neuromuscular diseases, Neurology and pain, Infectious diseases, Obesity, diabetes and heart disease, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
15 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.